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Introduction {#sec001}
============

Over the recent years, transplantation of livers retrieved after donation after circulatory death (DCD) has increased significantly in most parts of the world. Despite being associated to more ischemia/reperfusion lesions, and higher risks of primary non/poor function and ischemic cholangiopathy, such transplantations lead to similar post-transplant survivals as those achieved after donation after brain death (DBD)\[[@pone.0224890.ref001]--[@pone.0224890.ref005]\].

A point of attention is the clear experimental association between ischemia/reperfusion lesions and hepatocellular carcinoma (HCC) cell engraftment and growth \[[@pone.0224890.ref006]--[@pone.0224890.ref008]\]. Although still a matter of debate, clinical data suggest that ischemia/reperfusion is also associated with a higher risk of post-transplant cancer recurrence\[[@pone.0224890.ref008]--[@pone.0224890.ref011]\]. Overall, the more marginal the donor, the more ischemia/reperfusion lesion, and the higher the risk of recurrence, as illustrated by DCD donors with prolonged primary warm ischemia times carrying higher HCC recurrence rates compared to leaner counterparts \[[@pone.0224890.ref008]\].

In order to minimize such lesions, current DCD transplantation practices include the use of *in situ* (normothermic regional perfusion) and *ex vivo* (hypothermic oxygenated or normothermic machine perfusion) organ conditioning. These techniques can rescue injured organs and improve transplant outcomes \[[@pone.0224890.ref012], [@pone.0224890.ref013]\] \[[@pone.0224890.ref002]--[@pone.0224890.ref005], [@pone.0224890.ref014]\].

We previously reported that an *in situ* normothermic liver reperfusion can both reverse ischemia/reperfusion lesions, and the growth and engraftment of HCC cells\[[@pone.0224890.ref006]\]. Going one step further, the current study explores the potential of hypothermic and normothermic *ex vivo* machine perfusion to reduce HCC recurrence using a rat DCD liver transplantation model.

Materials and methods {#sec002}
=====================

Animals {#sec003}
-------

Female Fischer (F344) rats (Janvier Labs, Le Genest-Saint-Isle, France) were used for all experiments. Donors weighed 176 \[155--193\]g and recipients weighed 191 \[170--220\]g. They were cared for according to the international guidelines on animal care, and ethical approval was obtained from the ethical committee at the University of Geneva and from the Geneva veterinary authorities (GE53/17 and GE178/17). Rats were housed in open cages, with an enriched environment (Aspen Tapvei, Harjumaa, Estonia), under 12/12-h light/dark cycles and free access to water and standard chow (RM3 diet by Special Diet Services, Essex, UK). During the first four hours after surgery, animals were kept in standard individual cages, with the same enrichment, and having free access to water, and food. No formal randomization was applied when forming the study groups.

Study design {#sec004}
------------

We performed syngeneic arterialized orthotopic liver transplantations using 1h-DCD grafts. Prior to implantation, organs were treated *ex vivo* with either hypothermic oxygenated perfusion (HOPE) or normothermic blood-based perfusion (NORMO). Right after reperfusion, Fisher rat-derived JM-1\[[@pone.0224890.ref006]\] HCC cells were injected into the portal stream. Tumor growth was assessed by *ex vivo* MRI 28 days after transplantation. Controls were rats transplanted with fresh livers or 1h-DCD livers non-*ex vivo* perfused ([Fig 1](#pone.0224890.g001){ref-type="fig"}). Seven recipients were used in each group.

![Experimental design.\
CS = cold storage, HOPE = hypothermic oxygenated perfusion, NORMO = normothermic blood-based perfusion, HCC = hepatocellular carcinoma, MRI = magnetic resonance imaging.](pone.0224890.g001){#pone.0224890.g001}

DCD liver graft procurement {#sec005}
---------------------------

Rat liver procurement was performed under isoflurane anaesthesia (2.5--3.5%) and buprenorphine analgesia (0.1mg/kg subcutaneous given at induction). Liver isolation steps in the donor were performed as previously described \[[@pone.0224890.ref015]\]. In addition, the proper hepatic artery was carefully dissected and the gastroduodenal artery divided between 7--0 silk ties. The common hepatic artery was entirely dissected and ligated at its origin. A short fused silica stent (360 μm×150μm, IDEX, Oak Harbor, USA) was then inserted into its lumen and secured with a 7--0 silk tie (as previously described \[[@pone.0224890.ref016]\]).

Once the liver was completely isolated, the diaphragm was transected on each side. 1h-DCD time was measured from the onset of ventricular fibrillation, as previously described\[[@pone.0224890.ref017]\]. The liver was then flushed through the portal vein with 20mL cold IGL-1 solution (Institut Georges Lopez, Lyon, France), carrying 100UI of heparin.

All liver grafts had a total of 1h static cold storage in IGL-1 solution. The transitions from static conservation to *ex vivo* perfusions followed a strict timeline, as illustrated in [Table 1](#pone.0224890.t001){ref-type="table"}.

10.1371/journal.pone.0224890.t001

###### Graft cold storage-perfusion scheme.

![](pone.0224890.t001){#pone.0224890.t001g}

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Group   Donor flush   Static cold storage               N. Saline\       *Ex vivo* perfusion\   Static cold storage\   N. Saline\                               
                                                          flush duration                                                 cold flush duration                      
  ------- ------------- --------------------------------- ---------------- ---------------------- ---------------------- --------------------- ----------- ------ ------
  Fresh   IGL-1         IGL-1\                            1h               n/a                    n/a                                          n/a                1min
                        Backtable                                                                                                                                 

  DCD     IGL-1         IGL-1\                            1h               n/a                    n/a                                          n/a                1min
                        Backtable                                                                                                                                 

  DCD+\   IGL-1         IGL-1\                            0.5h             n/a                    IGL-1\                 2h                    IGL-1\      0.5h   1min
  HOPE                  Connection to perfusion chamber                                                                                        Backtable          

  DCD+\   IGL-1         IGL-1\                            0.5h             1 min                  ½ Blood\               2h                    IGL-1\      0.5h   1min
  NORMO                 Connection to perfusion chamber                                           ½ N. Saline                                  Backtable          
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------

*Ex Vivo* Hypothermic Oxygenated perfusion (HOPE) {#sec006}
-------------------------------------------------

Grafts were perfused on a Radnoti liver/kidney system (mod. 130003. Radnoti glass technology inc, Monrovia, CA, USA). Hypothermic perfusion was performed for 2 hours, applying the most commonly used parameters\[[@pone.0224890.ref012], [@pone.0224890.ref017]\]([Table 2](#pone.0224890.t002){ref-type="table"}). We chose to use non-complemented IGL-1 solution in order to match the 'HOPE for Human Liver Graft' clinical trial (NCT01317342. PI: Dr P. Dutowski, University Hospital of Zurich, Switzerland).

10.1371/journal.pone.0224890.t002

###### *Ex vivo* perfusions parameters.

![](pone.0224890.t002){#pone.0224890.t002g}

  -----------------------------------------------------------------------------------
                               HOPE                 NORMO
  ---------------------------- -------------------- ---------------------------------
  **Solution**                 IGL-1 (50mL)\        ½ blood ½ normal saline (50mL)\
                               Heparin (150UI)      Heparin (150UI)

  **Temperature**              4°C                  37°C

  **0**~**2**~ **pressure**    350mmHg              350mmHg

  **Haemoglobin saturation**   na                   99%

  **Hydrostatic Pressure**     4 mmHg               8 mmHg

  **Flow**                     Pressure dependent   Pressure dependent
  -----------------------------------------------------------------------------------

*Ex Vivo* Normothermic perfusion (NORMO) {#sec007}
----------------------------------------

Normothermic perfusion was performed for 2h under pressure control, with the same perfusion apparatus, chamber and circuit configurations used for hypothermic perfusion ([S1 Fig](#pone.0224890.s002){ref-type="supplementary-material"}, [Table 2](#pone.0224890.t002){ref-type="table"}). Grafts were perfused with adult male Fischer rat blood, diluted 1:1 with normal saline (total volume 50mL, haematocrit 20--22%). 150 UI of heparin were added to the solution in order to prevent clot formation. The perfusate was sampled for pH every 30 minutes. Bile was drained out the perfusion chamber through a fine silicon tubing and the production was recorded. Inflow and outflow haemoglobin saturation was measured with a saturometer (GO2 Achieve, NONIN, Plymouth, MN, USA) through the tubing, and graft oxygen uptake was calculated using the formula: $\Delta\ Saturation \times Hemoglobin \times \frac{perfusion\ flow}{liver\ mass} \times 1.34$ \[[@pone.0224890.ref018]\].

Liver transplantation {#sec008}
---------------------

Recipient operation was performed under isoflurane anesthesia (2.5--0.5%) and buprenorphine analgesia (0.02mg/kg subcutaneous given at induction). We used the standard technique developed in our lab\[[@pone.0224890.ref006], [@pone.0224890.ref015]\], with the addition of a stent-assisted arterial reconstruction. This anastomosis was performed after portal reperfusion and IVC reconstruction, by connecting the donor and the recipient's common hepatic arteries on a fused silica stent, as previously described\[[@pone.0224890.ref016]\]. Of note, all the recipients underwent spleno-systemic shunting by spleen subcutaneous transposition\[[@pone.0224890.ref019]\] 3 weeks prior to liver transplant. Fischer rats being particularly susceptible to portal clamping, this strategy allows to obtain high survival rates despite the use of damaged grafts\[[@pone.0224890.ref006]\]. Spleno-systemic shunting in fact reduces splanchnic congestion and the consequent release of vasoplegic molecules responsible for shock after portal unclamping\[[@pone.0224890.ref020]\].

After surgery, recipient rats were kept in heated single cages for 12h with free access to food and water. Analgesia (subcutaneous buprenorphine 0.005mg/kg) was administered every 8h during the first 48h.

HCC cells injection {#sec009}
-------------------

JM-1 cells\[[@pone.0224890.ref021]\] kindly provided by Dr G. Michalopoulos (Duke University Medical Center, Durham, NC), were maintained in Dulbecco's modified Eagle medium (Gibco, Paisley, UK) in standard culture conditions. Twenty minutes after portal reperfusion, 5x10^5^ JM-1 cells suspended in 600μl NaCl 0.9% were injected into the portal vein over 30 seconds, using a 25 G needle. The hole left by the needle was closed with a single 9--0 nylon 'figure of eight' suture.

Magnetic Resonance Imaging (MRI)-based HCC volume assessment {#sec010}
------------------------------------------------------------

Transplanted rats were sacrificed on post operatory day (POD) 28 by exsanguination under general anaesthesia. Explanted liver grafts were perfused and stored with formalin. Scans were performed on a 3.0T MR scanner (Nanoscan 3T, RS2D, Mundolsheim, France) with a birdcage coil of 3.5cm diameter. After automatic adjustment of the B0 homogeneity, T1w and T2w images were acquired. For T1w, a gradient echo 3D sequence was used with following parameters: field of view (FOV) 60x40 mm, matrix size 192x128, echo time (ET)/repetition time (RT) 3.8/50ms, flip angle 50°, 56 slices x 0.5mm thickness and 10 averages. For T2w images, a fast Spin Echo sequence was used with following parameters: FOV 60x40 mm, matrix size 192x128, ET/RT 87.5/4625ms, 35 slices x 0.8 mm thickness and 8 averages.

MRI images were loaded on OsiriX DICOM Viewer (Pixmeo, Geneva, Switzerland) and tumours' contour was manually marked on each slide. Volumes were then calculated using the built-in application.

Real-Time Polymerase Chain Reaction (PCR) {#sec011}
-----------------------------------------

qPCR assessments were performed on pre-implantation liver graft parenchyma. Total RNA was prepared and purified from frozen-crushed liver powder using the RNeasy Mini Kit (Qiagen, Germantown, MD), and according to the manufacturer's instructions. cDNA was synthesized from one μg of RNA by extending a mix of random primers with the High Capacity cDNA Reverse Transcription Kit in the presence of RNase Inhibitor (Applied Biosystems, Carlsbad, CA). The relative quantity of each transcript was normalized according to the expression of rplp1 (ribosomal protein large P1). Primers for HMGB1 (high mobility group box 1, NM_012963) and Hif1a (hypoxia-inducible factor 1, NM_024359.1) were bought from Qiagen. The other primers were homemade-designed and the sequences are available upon request. The following primers were used: rplp1 (ribosomal protein large P1, NM_001007604), Serpine1 (plasminogen activator inhibitor type 1, NM_012620.1), Hmox1 (heme oxygenase 1, NM_012580.2), irp94 (ischemia-responsive protein 94 (also known as Hsp4), AF_077354), and F3 (Tissue factor, NM_013057.2). Amplification reactions were performed in a total volume of 20μl using either a Thermocycler sequence detector (BioRad CFX96) with Takyon for SYBR Assay---No ROX (Eurogentec, Seraing, Belgium).

Transaminase and HMGB1 Serum Quantification {#sec012}
-------------------------------------------

24h post-transplant aspartate aminotransferase (AST), alanine aminotransferase (ALT), levels were measured on serum from centrifuged blood (11,000 rpm for 7 minutes at 4 °C) using a multiple strip machine (RefloVet Plus, Roche, Basel, Switzerland). HMGB1 ELISA assay was performed according to manufacturers' instructions (IBL International GMBH).

Light microscopy {#sec013}
----------------

Liver sections were stained with hematoxylin and eosin (Sigma, Buchs, Switzerland). Histological studies were performed blindly by an expert in liver anatomo-pathology.

Statistical analysis {#sec014}
--------------------

Data were expressed as median \[range\] and were analysed using Prism 7 (GraphPad Software Inc., CA, USA). Survivals were plotted according to Kaplan-Meier and compared using Log-rank (Mantel-Cox) test. All other continuous data were compared using Mann-Whitney test. The limit for statistical significance was set at p = 0.05.

Results {#sec015}
=======

DCD donors {#sec016}
----------

After cutting the diaphragm, respiratory arrest occurred within 7 \[4--11\]min in the DCD group, 6 \[4--10\]min in the DCD+HOPE, and 7 \[3--12\]min in the DCD+NORMO (all p\>0.05 in pairing assessments). Cardiac arrest occurred after 9 \[6--13\]min, 9 \[6--12\]min and 10 \[6--13\]min respectively (all p\>0.05).

Hypothermic perfusion of DCD liver grafts {#sec017}
-----------------------------------------

### Perfusion flow and resistance {#sec018}

The early HOPE perfusion flow was low (0.22 \[0.19--0.23\] mL/min/g). It increased during the first 30 minutes and reached a plateau after 1 hour (0.29 \[0.26--0.33\] mL/min/g; [Fig 2A](#pone.0224890.g002){ref-type="fig"} left). The calculated resistance followed the opposite trend, dropping from 2.40 \[2.28--2.71\] mmHg/(mL/min) to 1.72 \[1.58--2.00\] mmHg/(mL/min) ([Fig 2A](#pone.0224890.g002){ref-type="fig"} right) over the first 30 minutes of perfusion.

![*Ex vivo* perfused liver graft fluidodynamics and metabolism.\
a. Left, hypothermic perfusion of DCD grafts shows modest flow increase over time, under controlled pressure conditions. Right, hypothermic perfusion of DCD grafts shows modest resistance to flow reduction over time. b. Left, normothermic perfusion of DCD grafts shows significant flow increase over time, under controlled pressure conditions. Right, normothermic perfusion of DCD grafts shows significant resistance to flow reduction over time. c. Direct comparison of resistance to flow changes between hypothermic and normothermic *ex vivo* perfusion. d. Left, visual comparison of inflow vs. outflow haemoglobin saturation during normothermic perfusion. Second from left, oxygen uptake of DCD grafts on normothermic perfusion. It shows increasing oxygen consumption that reaches a plateau after one hour from perfusion initiation. Third from left, non-cumulative bile production of DCD grafts on normothermic perfusion. It shows constant rate bile production after the first hour of perfusion. Right, transaminase in the perfusion solution. It shows enzyme accumulation during perfusion, symptom of graft ischemia/reperfusion injury. DCD = donation after circulatory death, HOPE = hypothermic oxygenated perfusion, NORMO = normothermic blood-based perfusion, AST = aspartate aminotransferase, ALT alanine aminotransferase.](pone.0224890.g002){#pone.0224890.g002}

### Oxygen uptake and bile production {#sec019}

Inflow and outflow oxygen concentrations were similar in the perfusion solution (inflow 39.15 \[38.95--39.27\] %, outflow 39.05 \[38.83--39.18\] %, p\>0.5), suggesting no oxygen uptake (or lower than the instrument sensitivity). No bile production was detected under hypothermic perfusion.

Normothermic perfusion of DCD liver grafts {#sec020}
------------------------------------------

### Perfusion flow and resistance {#sec021}

The early NORMO perfusion flow was low (0.22 \[0.29--0.48\] mL/min/g). It rapidly increased during the first 30 minutes and reached a plateau after 1 hour (1.10 \[0.67--1.29\] mL/min/g; [Fig 2B](#pone.0224890.g002){ref-type="fig"} left). As expected, the calculated resistance showed the opposite trend, dropping from 2.45 \[2.18--2.73\] mmHg/(mL/min) to 1.07 \[0.97--1.26\] mmHg/(mL/min)([Fig 2B](#pone.0224890.g002){ref-type="fig"} right) over the first 30 minutes of normothermic perfusion. As shown in [Fig 2C](#pone.0224890.g002){ref-type="fig"} the initial resistance to flow was equal in all DCD grafts. However, the normothermic perfusion allowed for a more consistent reduction in perfusion resistance (-63%) compared to the hypothermic approach (-28.33%).

### Oxygen uptake and bile production {#sec022}

The early calculated oxygen uptake of the DCD liver grafts was low (0.0016 \[0.0013--0.0025\] mL/min/g). It rapidly increased to reach a plateau (0.018 \[0.0015--0.019\] mL/min/g) after 30 minutes ([Fig 2D](#pone.0224890.g002){ref-type="fig"}). Bile production followed the same pattern, being 12.6 \[6.1--20.2\] μL/g over the first 30 minutes, then constantly around 20 μL/g every following half hour ([Fig 2D](#pone.0224890.g002){ref-type="fig"}).

### Ischemia/reperfusion injury assessment {#sec023}

DCD grafts appeared markedly congested and firm. After the initial cold flushing, some areas remained only partially washed out (red large patches in [Fig 3A](#pone.0224890.g003){ref-type="fig"}, right). This phenomenon was possibly related to a local vasospasm and perivascular oedema.

![Ischemia/reperfusion injury in DCD *ex vivo* perfused liver grafts.\
a. 1h DCD donor prior and cold flushing. Arrows indicating the wide cut in the diaphragm.b. Comparison of DCD grafts during hypothermic and normothermic perfusion and after reperfusion in the recipient. Normothermic treatment allowed for more homogeneous perfusion of the grafts and reduction of the local vasospasm. c. Histological comparison of liver grafts prior to implantation. All DCD livers presented similar amount of apoptotic hepatocytes (black arrows). DCD and DCD+HOPE grafts presented loss of intercellular cohesion. DCD+NORMO grafts showed loss of intercellular cohesion to a minor extent compared to DCD and DCD+NORMO grafts. DCD = donation after circulatory death, HOPE = hypothermic oxygenated perfusion, NORMO = normothermic blood-based perfusion.](pone.0224890.g003){#pone.0224890.g003}

During the hypothermic perfusion the large dark areas were effectively washed out ([Fig 3B](#pone.0224890.g003){ref-type="fig"}, comparison between the 1st and 2nd pictures from the left). However, the grafts never recovered fully, as demonstrated by the inhomogeneous colour of the liver parenchyma after the final flush ([Fig 3B](#pone.0224890.g003){ref-type="fig"}, 4^th^ column from the left). Further, we still observed macroscopic perfusion abnormality 20 minutes after reperfusion ([Fig 3B](#pone.0224890.g003){ref-type="fig"}, last two pictures).

During normothermic perfusion, concomitantly to the drop of vascular resistance, most of the hypo-perfused areas disappeared ([Fig 3C](#pone.0224890.g003){ref-type="fig"}, 2nd picture from the left), leaving almost no mark after the final flush ([Fig 3C](#pone.0224890.g003){ref-type="fig"}, 3rd picture from the left). Only small peripheral areas did not recover, and were still visible 20 minutes after reperfusion ([Fig 3C](#pone.0224890.g003){ref-type="fig"}, last two pictures).

Pre-implantation biopsies showed decreased congestion in the DCD-HOPE and the DCD-NORMO, compared to the non-perfused DCD grafts. By contrast all DCD grafts had similar increased number of apoptotic hepatocytes (black arrows in [Fig 3C](#pone.0224890.g003){ref-type="fig"}) and a loss of intercellular cohesion (compared with the Fresh grafts).

Evidence indicates that Irp94, Hmox1, Hif1a, Serpine1, HMGB1 and F3 genes expression is up-regulated in case of liver hypoxia and ischemic injury\[[@pone.0224890.ref022]--[@pone.0224890.ref025]\]. The mRNA levels of Serpine 1, F3 and Hmox were increased in the DCD grafts after normothermic perfusion, while there was no difference in the expression of these genes in all other groups ([Fig 4A](#pone.0224890.g004){ref-type="fig"}, left column. Fresh vs. NORMO p\<0.005, DCD vs. NORMO p\<0.005, HOPE vs. NORMO p\<0.005). Irp94 and Hif1a expression was up-regulated both in the DCD+HOPE and DCD+NORMO, although to a greater extent in the latter group ([Fig 4A](#pone.0224890.g004){ref-type="fig"}, right column. DCD+HOPE vs. DCD+NORMO p\<0.05). No difference was found in the expression of HMGB1 among all pre-implantation grafts.

![Pre- and post transplant ischemia/reperfusion injury assessment.\
a. Pre implantation graft I/R-induced genes expression (fold increase). The mRNA levels of Serpine 1, F3 and Hmox were increased in the DCD grafts after normothermic perfusion, while there was no difference in the expression of these genes in all other groups (Fresh vs. NORMO p\<0.005, DCD vs. NORMO p\<0.005, HOPE vs. NORMO p\<0.005). Irp94 and Hif1a expression was up-regulated both in the DCD+HOPE and DCD+NORMO, although the latter to a greater extent (DCD+HOPE vs. DCD+NORMO p\<0.05). No difference was found in the expression of HMGB1 among all pre implantation grafts. b. 24h post transplant serum transaminase. DCD and DCD+HOPE recipients had very high levels of both AST (Fresh vs. DCD p = 0.012, Fresh vs. DCD+HOPE p = 0.016) and ALT (Fresh vs. DCD p = 0.006, Fresh vs. DCD+HOPE p = 0.008). DCD+NORMO recipients by contrast showed lower levels of both liver enzymes (DCD+HOPE vs. DCD+NORMO p = 0.016 for both AST and ALT). c. 24h post transplant serum HMGB1. Circulating HMGB1 was lower in the Fresh liver recipients, while no difference was found among the DCD recipients, whether *ex-vivo* perfused or not (Fresh vs. DCD, DCD+HOPE, DCD+NORMO p\<0.05). HMGB1 = high mobility group box 1, Hif1a = hypoxia-inducible factor 1, rplp1 = ribosomal protein large P1, Serpine1 = plasminogen activator inhibitor type 1, Hmox1 = heme oxygenase 1, irp94 = ischemia-responsive protein 94, I/R = Ischemia/reperfusion, DCD = donation after circulatory death, HOPE = hypothermic oxygenated perfusion, NORMO = normothermic blood-based perfusion, AST = aspartate aminotransferase, ALT alanine aminotransferase.](pone.0224890.g004){#pone.0224890.g004}

24 hours after transplantation Fresh liver recipients showed normal plasma levels of ALT and AST. DCD and DCD+HOPE recipients had very high levels of both AST (Fresh vs. DCD p = 0.012, Fresh vs. DCD+HOPE p = 0.016) and ALT (Fresh vs. DCD p = 0.006, Fresh vs. DCD+HOPE p = 0.008). DCD+NORMO recipients by contrast showed lower levels of both liver enzymes (DCD+HOPE vs. DCD+NORMO p = 0.016 for both AST and ALT, [Fig 4B](#pone.0224890.g004){ref-type="fig"}).

The nuclear factor HMGB1 is an early mediator of injury and inflammation after liver ischemia-reperfusion\[[@pone.0224890.ref026]\]. Serum levels of HMGB1 were lower in the Fresh liver recipients 24 hours after transplantation, while no difference was found among the DCD recipients, whether *ex-vivo* perfused or not (Fresh vs. DCD, DCD+HOPE, DCD+NORMO p\<0.05. [Fig 4C](#pone.0224890.g004){ref-type="fig"})

Post-Transplant Health, Survival and HCC development {#sec024}
----------------------------------------------------

All animals recovered from the transplant procedure. DCD recipients were more prone to bleeding from the liver surface, which was not the case in the DCD+NORMO recipients. None required blood transfusion or volume replacement in the Fresh group. Conversely, two recipients in the DCD and three recipients in the DCD+HOPE group were transfused with 0.5mL of syngeneic full blood, in order to compensate an estimated blood loss of 0.4--0.7 mL.

All DCD recipients were mildly lethargic on the first post-operative day, but DCD+NORMO ones being slightly more active. One animal from the DCD+HOPE and one from the DCD+NORMO groups died on POD 1 ([Fig 5A](#pone.0224890.g005){ref-type="fig"}), after having undergone open surgical liver biopsy (see discussion). All the other rats survived till the end of the follow-up (28 days), except for one DCD+NORMO recipient which died of obstructive cholangitis because of one HCC nodule located at the hilum.

![Post transplant survival and HCC development.\
a. Post liver transplant survival. b. POD 28 HCC volumes. Tumour growth was homogeneous between the Fresh recipients. Non *ex-vivo* perfused DCD liver recipients developed larger tumours (Fresh vs. DCD p = 0.0006). DCD+HOPE and DCD+NORMO showed more variability in HCC size. DCD+HOPE tumours were overall larger than those of the Fresh recipients (Fresh vs. DCD+HOPE p = 0.014). DCD+NORMO were not significantly different from the Fresh group (Fresh vs. DCD+NORMO p = 0.62, DCD vs. DCD+NORMO p = 0.23) POD = postoperative day, HCC = hepatocellular carcinoma, DCD = donation after circulatory death, HOPE = hypothermic oxygenated perfusion, NORMO = normothermic blood-based perfusion.](pone.0224890.g005){#pone.0224890.g005}

All recipients developed HCC nodules. Tumor implant and growth was extremely homogeneous between the Fresh recipients, with a total tumour volume (TTV) range spanning from 0.92 to 2.10 cm^3^ only (median 1.60 cm^3^). In contrast, non-*ex-vivo* perfused DCD liver recipients constantly developed larger tumours (TTV: 3.25 \[2.49--8.72\] cm^3^, Fresh vs. DCD p = 0.0006), in line with our previous study \[[@pone.0224890.ref006]\]. DCD+HOPE and DCD+NORMO recipients showed more variability in HCC size. DCD+HOPE tumours were overall larger than those of the Fresh recipients (TTV: 6.44\[1.30--16.97\]cm^3^, Fresh vs. DCD+HOPE p = 0.014). DCD+NORMO were not significantly different from the Fresh group (TTV: 1.52\[0.08--9.90\]cm^3^, Fresh vs. DCD+NORMO p = 0.62, DCD vs. DCD+NORMO p = 0.23). All recipients developing larger tumours (TTV\>4cm^3^) displayed peritoneal carcinomatosis at time of autopsy. Conversely, none of the recipients developed lung nodules.

Discussion {#sec025}
==========

This study confirms that the use of marginal, ischemic rat liver grafts increases HCC growth after transplantation. However, hypothermic oxygenated and normothermic *ex vivo* perfusions did not bring a measurable improvement in the post-transplant HCC volumes. This observation is in contrast with our previous observation utilizing liver grafts with a 30-minute warm ischemia (unlike 60 minutes in the present experiments), where we found that *in situ* normothermic reperfusion prior to organ procurement mitigated post-transplant cancer recurrence\[[@pone.0224890.ref006]\].

Hypothermic and normothermic perfusions proved effective in rescuing liver grafts from ischemic injuries\[[@pone.0224890.ref001], [@pone.0224890.ref012]--[@pone.0224890.ref014], [@pone.0224890.ref017], [@pone.0224890.ref027], [@pone.0224890.ref028]\]. While the former is simpler approach that requires no blood or additives, the latter has the advantage of mimicking physiological conditions, but requires more sophisticated equipment and involves higher costs\[[@pone.0224890.ref029]\]. Given that there is no consensus on whether one strategy is more effective than the other\[[@pone.0224890.ref030]\], and none of them was tested in a cancer setting, we challenged both.

Intimal barotrauma has been identified as a major factor in the failure of achieving beneficial *ex vivo* perfusion\[[@pone.0224890.ref012], [@pone.0224890.ref031]\]. Knowing this, we closely monitored the fluid dynamics of the grafts throughout the process and continuously adjusted the perfusion rate in order to maintain low inflow pressures. Therefore, even the minor pressure fluctuations typical of peristaltic pumps were successfully compensated by the use of a semi-open perfusion chamber system.

In DCD liver grafts, intravascular resistance increases due to perivascular swelling \[[@pone.0224890.ref032]\], the role of small clots being controversial\[[@pone.0224890.ref033]\]. We observed that hypothermic perfusion could only marginally reduce this phenomenon, its effect being likely generated by the mechanical washout of residual blood in higher resistance areas. Conversely, normothermic perfusion was able to restore almost normal fluid dynamics as early as 1 hour after its initiation. Similarly, liver grafts remained profoundly metabolically hypoactive during the hypothermic perfusion, as demonstrated by the undetectable oxygen uptake, the absence of bile production and no increase in Serpine1, F3 and Hmox expressions. By contrast, normothermic grafts were actually functioning close to their normal physiology, with only small areas of focal necrosis which never recovered during the 2h perfusion.

Unlike previous studies on hypothermic and normothermic perfusions of prolonged-ischemia rat liver grafts\[[@pone.0224890.ref012], [@pone.0224890.ref017], [@pone.0224890.ref034]\], we could not appreciate any difference in post-transplant survival. This observation may have multiple explanations. First, we used arterialized grafts. Although it does not affect survival in rodents transplanted with uninjured livers \[[@pone.0224890.ref035], [@pone.0224890.ref036]\], it has been proven to help function recovery in ischemic grafts\[[@pone.0224890.ref037]\]. Second, spleno-systemic shunts protected the recipients from any portal clamping-related shock, avoiding the synergy bad organ/surgical stress, causing deaths non necessarily related to the status of the grafts only. Third, our extensive expertise with rodent liver transplantation\[[@pone.0224890.ref006], [@pone.0224890.ref015], [@pone.0224890.ref036]\] helped designing a study with few biases.

Exposing the grafts to longer perfusion times would not have affected the outcomes after hypothermic perfusion, as studies demonstrated a plateauing effect after one hour\[[@pone.0224890.ref001], [@pone.0224890.ref002], [@pone.0224890.ref012], [@pone.0224890.ref013], [@pone.0224890.ref017], [@pone.0224890.ref027], [@pone.0224890.ref031]\]. In contrast, it takes at least two hours for a normothermic perfusion to have an impact, and we set both NORMO and HOPE protocols at this perfusion time. Moreover, we made this choice to avoid the need for a dialysis circuit or complicated nutrients and electrolytes complementation of the perfusate\[[@pone.0224890.ref028], [@pone.0224890.ref034]\]. This aspect represents a limitation of this study, since longer normothermic perfusions may have led to a better organ recovery\[[@pone.0224890.ref038]\] and potentially to a decreased HCC implantation/growth.

Another limitation in this study is the absence of a post-reperfusion biopsy in the recipients. It was our original plan to perform a surgical biopsy 24h after implant. However, since most of the recipients in the DCD and DCD+HOPE groups were not fit enough on POD1 to cope with another surgery, we skipped this step to meet local veterinary requirements.

Only two well characterized HCC cell lines have been isolated from inbred rat hepatomas: JM-1 in Fischer and McA-RH7777 in Buffalo rats\[[@pone.0224890.ref039]\]. Since hepatocarcinoma can be very heterogeneous in humans\[[@pone.0224890.ref040]\], we aimed at reproducing the current experiments with McA-RH7777 cells. Unfortunately, we found Buffalo rats to have extreme abdominal vascular variations that made the transplantation model unsuitable for optimal standardization. If having failed to use a second cell line may have reduced the translational value of this study, our findings still find support in the behaviour of similar tumors in other species\[[@pone.0224890.ref041]\]. In particular, our group has demonstrated the increased risk of HCC recurrence in ischemic mouse livers\[[@pone.0224890.ref007], [@pone.0224890.ref008]\].

Overall, the study confirms that ischemic liver grafts are more likely to develop worse HCC recurrence. In the present setting, hypothermic perfusion did not bring a measurable benefit in terms of cancer implantation/growth reduction. Normothermic perfusion helped organ function recovery, but we were not able to demonstrate a consistent effect in reducing cancer burden. Further studies with shorter ischemic times and longer normothermic perfusion would be of interest.

Supporting information {#sec026}
======================

###### NC3Rs ARRIVE guidelines checklist.

(DOCX)

###### 

Click here for additional data file.

###### Perfusion chamber and graft connection.

The perfusion chamber is a semi-open system composed of a lower chamber (35x10mm petri dish) glued to the inferior surface of a larger open chamber (petri dish 60x15mm). The two chambers communicate through three 2mm holes in the floor of the upper chamber. Chambers are filled with cold solution and liver graft lays into the upper chamber (the SHVC being previously tied). The vena porta (inflow) and the IVC (outflow) are connected to cannulas fitting their size without excessive stretching. The IVC cannula is connected to a soft silicon tubing linking the upper and the lower chamber. The perfusion solution runs through the graft and is collected into the lower chamber without contaminating the fluid in the upper chamber. The solution collecting into the lower chamber goes to the pump through a single silicon tubing. Of note, the cyclic pressure fluctuations (typical of peristaltic pumps) potentially causing reduced aspiration in the lower chamber are compensated by the holes interconnecting the two chambers. IVC = infrahepatic vena cava.

(TIFF)

###### 

Click here for additional data file.

We wish to thank Maria-Louisa Izamis and Korkut Uygun for the helpful suggestions.

HCC

:   hepatocellular carcinoma

DCD

:   donation after circulatory death

HOPE

:   hypothermic oxygenated perfusion

NORMO

:   normothermic blood-based perfusion

DBD

:   donation after brain death

POD

:   post operatory day

FOV

:   field of view

ET

:   echo time

RT

:   repetition time

MRI

:   magnetic resonance imaging

PCR

:   polymerase chain reaction

HMGB1

:   high mobility group box 1

Hif1a

:   hypoxia-inducible factor 1

Rplp1

:   ribosomal protein large P1

Serpine 1

:   plasminogen activator inhibitor type 1

Hmox1

:   heme oxygenase 1

Irp94

:   ischemia-responsive protein 94

I/R

:   ischemia/reperfusion

AST

:   aspartate aminotransferase

ALT

:   alanine aminotransferase

TTV

:   total tumor volume
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2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: No

Reviewer \#2: Yes
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3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes
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4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes
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5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Oldani G. and co authors, in the current paper, examined the impact of hypothermic and normothermic ex vivo liver perfusions on JM-1 neoplastic cells growth in transplanted rat liver. In comparison with fresh transplanted rats, both methods of "ex vivo" perfusion determined increase of HCC growth, thus suggesting a role in ischemia-reperfusion injury in supporting tumor proliferation and spreading.

Comments

1\) The results of the study were based on the use of JM-1 line only. Several other HCC cell lines are available and, on the other hand, HCC in human denotes several phenotypic differences between subjects. For all the above, the authors should comment the limits of the extrapolation of these results in the setting of HCC in human liver transplantation.

2\) Since three groups were included in the study, ANOVA should be the appropriate test for statistical comparison.

3\) The study is mainly observational and putative mechanisms relating ischemia-reperfusion injury to increase tumor proliferation should be at list mentioned in discussion. In my opinion, this line of research would benefit in the future by testing HCC growth and spreading genes in "in vitro" easily adaptable systems.

Reviewer \#2: This is a very interesting study and the findings are very robust.

The group performed DDLT using DCD grafts in rats compared with fresh liver grafts. The DCD grafts were divided into two groups using HOPE or NORMO as the machine perfusion. While the findings of transaminases post-machine perfusion was somewhat expected, I find it difficult to understand why there are more peritoneal metastasis in the study, and it was particularly related to the tumor size.

The authors tried to induce tumour growth by injecting the designated tumour cells with HCCs via portal vein after repercussion and monitor for tumor growth. However, how does that translate into the distribution of tumours in different parts of the liver was not explained. More importantly, I am curious to know how these larger tumours were able to develop into peritoneal carcinomatosis within 28 days and the details of this data was not available in the results section.

Overall, it is an interesting study, proving the concept that the ischaemic environment promotes tumour progression but the actual pathological process involved, particularly from the immunological aspects was not clear.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Reviewer \#1:

1\) The results of the study were based on the use of JM-1 line only. Several other HCC cell lines are available and, on the other hand, HCC in human denotes several phenotypic differences between subjects. For all the above, the authors should comment the limits of the extrapolation of these results in the setting of HCC in human liver transplantation.

R1: Thank you for the appropriate comment. We implemented the discussion explaining why we were not able to use other cell lines, which was our original plan.

2\) Since three groups were included in the study, ANOVA should be the appropriate test for statistical comparison.

R2: Thank you for the comment. We partially disagree since our aim was to compare each study group directly with the control groups (being the results of the two control groups, predicted by our previous studies). For completeness, we ran ANOVA tests to follow the suggestion and the results did not change.

3\) The study is mainly observational and putative mechanisms relating ischemia-reperfusion injury to increase tumor proliferation should be at list mentioned in discussion. In my opinion, this line of research would benefit in the future by testing HCC growth and spreading genes in "in vitro" easily adaptable systems.

R3: Thank you for the comment. With this study we did not aim to prove mechanisms, as we already performed more targeted experiments in simpler settings in the past. We implemented the discussion including these citations.

Reviewer \#2: This is a very interesting study and the findings are very robust.

1\) The group performed DDLT using DCD grafts in rats compared with fresh liver grafts. The DCD grafts were divided into two groups using HOPE or NORMO as the machine perfusion. While the findings of transaminases post-machine perfusion was somewhat expected, I find it difficult to understand why there are more peritoneal metastasis in the study, and it was particularly related to the tumor size.

R1: Thank you for the comment. We found more peritoneal involvement when tumors were large enough to infiltrate beyond liver capsule. We did not assess whether these tumors had switched to more aggressive phenotypes.

2\) The authors tried to induce tumour growth by injecting the designated tumour cells with HCCs via portal vein after repercussion and monitor for tumor growth. However, how does that translate into the distribution of tumours in different parts of the liver was not explained. More importantly, I am curious to know how these larger tumours were able to develop into peritoneal carcinomatosis within 28 days and the details of this data was not available in the results section.

R2: Thank you for the comment. It was very hard to identify a tumor distribution pattern. Rat livers are small, and tumors grow quickly, passing from non being detectable to merging nodules in few days.

3\) Overall, it is an interesting study, proving the concept that the ischaemic environment promotes tumour progression but the actual pathological process involved, particularly from the immunological aspects was not clear.

R3: Thank you for the comment. We have already published (on PLOS) the role of the immune system on cancer recurrence after transplant, using a similar model. It would have been interesting to assess it in this context too (as many other things), but it was not the focus of the study.

We hope this revision satisfies your expectations.
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We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.
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Ezio Laconi, MD, PhD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: (No Response)

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: (No Response)

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: (No Response)

Reviewer \#2: Yes
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5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: (No Response)

Reviewer \#2: Yes
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6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: (No Response)

Reviewer \#2: The revision has addressed all the issues that I have raised.

However, the authors should still try to explain how the tumours are distributed after being injected into the Rat\'s liver. Albeit the liver of the rats are small, how this end up in the peritoneum as carcinomatosis is not explained.
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7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).
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Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Ezio Laconi

Academic Editor

PLOS ONE

[^1]: **Competing Interests:**The authors have declared that no competing interests exist.
